Xtl Biopharmaceuticals (XTLB) Net Cash Flow Growth (1y) (2010 - 2016)
Xtl Biopharmaceuticals (XTLB) Net Cash Flow Growth (1y) (2010 - 2016) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 53.46% |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | -116.73% |
| Dec 31, 2015 | 2,491.77% |
| Sep 30, 2015 | -53.68% |
| Jun 30, 2015 | 4,951.67% |
| Dec 31, 2014 | 87.78% |
| Sep 30, 2014 | -110.35% |
| Jun 30, 2014 | 109.06% |
| Mar 31, 2014 | -585.71% |
| Dec 31, 2013 | -22.56% |
| Sep 30, 2013 | 3,651.19% |
| Jun 30, 2013 | 65.68% |
| Mar 31, 2013 | -100.94% |
| Dec 31, 2012 | -39.74% |
| Sep 30, 2012 | 181.55% |
| Jun 30, 2012 | -491.72% |
| Mar 31, 2012 | 1,002.63% |
| Dec 31, 2011 | -133.75% |
| Sep 30, 2011 | -108.31% |
| Jun 30, 2011 | -185.96% |
| Mar 31, 2011 | -207.45% |